Compare Fidelity National Information Servcs Inc (FIS) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Fidelity National Information Servcs Inc vs State Street SPDR S&P Biotech ETF — how do they compare? Fidelity National Information Servcs Inc trades at $41.67 (market cap $21.24B), while State Street SPDR S&P Biotech ETF trades at $153.68. The key difference: Fidelity National Information Servcs Inc pays a 4.09% dividend while State Street SPDR S&P Biotech ETF pays none, and State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, Fidelity National Information Servcs Inc nearer its low. Which is the better fit depends on your goals.
| FIS | XBI | |
|---|---|---|
Market Cap | $21.24B | — |
Sector | Technology | Broad Market / Factor |
52-Week High | $81.94 | $164.28 |
52-Week Low | $37.72 | $85.16 |
Enterprise Value | $41.63B | — |
Dividend Yield | 4.09% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FIS (Fidelity National Information Services) trades at $40.58, down 3.22% on the day, with a bearish technical signal and neutral oscillators. The company shows improving fundamentals with Q1 2026 EPS beating expectations at $1.36 versus $1.29, and analyst consensus remains strong with 21 Buy ratings and a $52.57 price target. Recent business developments include winning Frankfurt International Bank as a cloud banking client and receiving industry awards for AI-embedded risk technology.
The outlook presents a value opportunity with a low P/E of 7.97 and improving profit margins, though execution risks persist from the Worldpay divestiture and net cash flow volatility. Upside potential exists if the company capitalizes on its $42 billion market opportunity in digital payments and maintains its recent earnings momentum.
XBI trades at $155.19, down 0.23% on the day, with a bullish technical signal from moving averages. Recent news highlights strong biotech sector momentum, with the ETF gaining nearly 17% in a month (24/7 Wall Street, 2026-07-06). Analyst consensus is neutral with a single hold rating, while technical indicators show a neutral RSI and mixed ADX signals. Support is seen near $153, with resistance at $157.
The outlook for XBI is supported by sector strength and M&A activity, but high volatility and a neutral analyst stance suggest cautious optimism. Key risks include regulatory uncertainty and macroeconomic pressures, requiring careful risk management for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Fidelity National Information Servcs Inc
Fidelity National Information Services' legacy operations provide core and payment processing services to banks, but its business has expanded over time. By acquiring Sungard in 2015, the company now provides record-keeping and other services to investment firms. With the acquisition of Worldpay in 2019, FIS now provides payment processing services for merchants and holds leading positions in the United States and United Kingdom. About a fourth of revenue is generated outside North America.
Read more on FIS →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
